GentiBio
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Smartlabs 6 Tide St Fl 2, Boston, Massac...Website
www.gentibio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About GentiBio
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. The company was founded in 2020 and is headquartered in Boston, Massachusetts.Explore more
GentiBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GentiBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if GentiBio has recently received funding, and reach out quickly before it becomes old news!
GentiBio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when GentiBio launches new products
Click to see if GentiBio had a recent Job posting/layoffs
Check out if GentiBio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at GentiBio
Funding: Get notified immidiatlly once GentiBio has new funding data
Earning: See what the market has to say on GentiBio recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to GentiBio
Compare insights from companies similar to GentiBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
GentiBio
<$5M
11-50
Private
$157M
2020
SP
Stanford PengPresident, Research & Development, Alpine Immune Sciences
Company Profile Activity
Activity Insights
GentiBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GentiBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GentiBio.
GentiBio financials insights
Gather financial insights about GentiBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$157M
GentiBio Tech Stack
A closer look at the technologies used by GentiBio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Clinical Operations
Person-Based
Events, Pharmaceuticals
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
GentiBio News & Media
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- GentiBio, a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs), announced today the appointment of Mark Bach, M.D., Ph.D. as Chief Medical Officer. Dr. Bach brings over 30 years of experience in...GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
--Encouraging Data Strongly Support Clinical Development of GNTI-122 in T1D-- CAMBRIDGE, Mass., Oct. 11, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs) therapies for autoimmune, auto-inflammatory, alloimmune and...GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
-- Tregs Potency, Survival and Engraftment Significantly Enhanced Through Delivery of Engineered Tregs with Tunable IL-2 Signaling Support CAMBRIDGE, Mass., Sept. 14, 2022 /PRNewswire/ -- GentiBio, Inc., a biotherapeutics company developing engineered T regulatory (Treg) cells (EngTregs)...GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases
Collaboration combines GentiBio's best-in-class engineered regulatory T cell platform with Bristol Myers Squibb's leadership in cell therapy and immunology drug development GentiBio to receive upfront cash payment, up to $1.9 billion in potential future development and commercial...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GentiBio
Sign Up For FreeTo access detailed company insights
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. The company was founded in 2020 and is headquartered in Boston, Massachusetts.... Read More
